Subscribe to our newsletter to receive the latest product updates and special offers

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

Last Close
Jul 24 04:00PM ET
Dollar change
Percentage change
Index- P/E- EPS (ttm)-2.68 Insider Own2.41% Shs Outstand18.34M Perf Week-7.10%
Market Cap4.13M Forward P/E- EPS next Y-1.36 Insider Trans0.00% Shs Float17.90M Perf Month0.36%
Income-40.13M PEG- EPS next Q-0.41 Inst Own12.33% Short Float1.10% Perf Quarter-41.96%
Sales3.14M P/S1.32 EPS this Y53.64% Inst Trans-3.47% Short Ratio0.21 Perf Half Y-66.55%
Book/sh-0.80 P/B- EPS next Y6.83% ROA-115.60% Short Interest0.20M Perf Year-77.06%
Cash/sh1.28 P/C0.18 EPS next 5Y- ROE-1014.13% 52W Range0.19 - 1.12 Perf YTD-68.81%
Dividend Est.- P/FCF- EPS past 5Y21.28% ROI-192.78% 52W High-79.89% Beta1.05
Dividend TTM- Quick Ratio3.60 Sales past 5Y2058.58% Gross Margin28.12% 52W Low17.91% ATR (14)0.03
Dividend Ex-Date- Current Ratio3.60 EPS Y/Y TTM55.76% Oper. Margin-1116.18% RSI (14)35.16 Volatility8.69% 10.55%
Employees23 Debt/Eq- Sales Y/Y TTM1194.50% Profit Margin-1278.03% Recom1.00 Target Price4.00
Option/ShortYes / Yes LT Debt/Eq- EPS Q/Q55.78% Payout- Rel Volume0.14 Prev Close0.23
Sales Surprise- EPS Surprise23.40% Sales Q/Q233.33% EarningsMay 15 BMO Avg Volume956.37K Price0.23
SMA20-0.12% SMA50-29.95% SMA200-55.07% Trades Volume134,286 Change-0.35%
Date Action Analyst Rating Change Price Target Change
Mar-15-21Initiated Oppenheimer Perform
Sep-14-20Initiated Guggenheim Buy $5
Aug-28-20Initiated Cantor Fitzgerald Overweight $5
May-31-19Resumed H.C. Wainwright Buy
Nov-05-18Downgrade H.C. Wainwright Buy → Neutral
Oct-12-18Downgrade Needham Buy → Hold
Oct-10-18Downgrade Jefferies Buy → Hold
Nov-08-17Reiterated Needham Buy $9 → $7
Oct-16-17Downgrade Barclays Overweight → Equal Weight $15 → $2.50
Oct-12-17Reiterated H.C. Wainwright Buy $8 → $7
Jul-08-24 09:15AM
Jun-20-24 07:00AM
May-15-24 12:53PM
07:13AM Loading…
Apr-01-24 07:13AM
Dec-28-23 02:00PM
Dec-27-23 09:10AM
Dec-04-23 07:02AM
Nov-30-23 07:00AM
Nov-15-23 03:08PM
Nov-14-23 07:35AM
07:00AM Loading…
Nov-09-23 07:00AM
Oct-16-23 07:00AM
Oct-02-23 07:00AM
Sep-06-23 07:01AM
Aug-14-23 07:07AM
Jul-20-23 07:00AM
Jun-26-23 07:00AM
May-31-23 07:00AM
May-30-23 07:00AM
May-15-23 09:01PM
May-11-23 05:25PM
07:00AM Loading…
May-09-23 07:00AM
May-08-23 07:00AM
May-03-23 07:00AM
Apr-09-23 07:34PM
Mar-30-23 07:02AM
Mar-27-23 07:00AM
Mar-09-23 10:21AM
Mar-07-23 07:00AM
Feb-14-23 08:00AM
Jan-09-23 07:00AM
Dec-08-22 07:00AM
Nov-29-22 07:00AM
Nov-16-22 08:00AM
Nov-09-22 04:01PM
Nov-07-22 07:00AM
Oct-24-22 07:00AM
Sep-07-22 07:00AM
Aug-16-22 12:00PM
Aug-12-22 06:48AM
Aug-11-22 08:25AM
Aug-08-22 07:00AM
Jul-29-22 05:27PM
Jul-28-22 09:41AM
Jun-14-22 07:00AM
Jun-10-22 07:00AM
May-18-22 04:05PM
May-11-22 08:15AM
May-10-22 07:55AM
May-09-22 07:00AM
Apr-28-22 03:02PM
Apr-20-22 07:00AM
Apr-18-22 07:00AM
Apr-13-22 04:05PM
Mar-31-22 11:26AM
Mar-30-22 07:00AM
Mar-14-22 08:15AM
Mar-07-22 06:55PM
Mar-05-22 06:43AM
Feb-03-22 07:00AM
Jan-28-22 02:01PM
Jan-27-22 09:00AM
Jan-03-22 04:05PM
Dec-14-21 11:06AM
Dec-13-21 07:00AM
Nov-15-21 12:25PM
Nov-11-21 07:00AM
Nov-08-21 07:00AM
Oct-25-21 03:01PM
Oct-13-21 07:00AM
Oct-01-21 10:40AM
Sep-30-21 09:13AM
Sep-17-21 07:00AM
Sep-09-21 07:00AM
Aug-30-21 07:00AM
Aug-25-21 07:00AM
Aug-20-21 09:05AM
Aug-12-21 09:55AM
Trevena, Inc. is a biopharmaceutical company, which focuses on developing and commercializing novel medicines for patients affected by central nervous system, or CNS, disorders. Its product candidates include Oliceridine injection, TRV250, TRV734, and TRV045. The company was founded by Maxine Gowen, Robert Joseph Lefkowitz, Scott DeWire, Howard A. Rockman, Jonathan Violin, and Erin Whalen on November 9, 2007 and is headquartered in Chesterbrook, PA.